期刊文献+

High plasma CD40 ligand level is associated with more advanced stages and worse prognosis in colorectal cancer

在线阅读 下载PDF
导出
摘要 BACKGROUND Colorectal cancer(CRC)is often associated with elevated platelet count(>400×10^(9)/L),known as thrombocytosis.The role of CD40 ligand(CD40L),a member of the tumor necrosis factor family,is controversial in CRC.Circulating CD40L is higher in CRC,but its relationship with disease staging and local and distant metastasis is not clear.Although most of the circulating CD40L is produced by platelets,no previous study investigated its relationship with CRC-related thrombocytosis.AIM To investigate the role of CD40L to predict the outcome of CRC and its relation to thrombocytosis.METHODS A total of 106 CRC patients and 50 age and sex-matched control subjects were enrolled for the study.Anamnestic data including comorbidities and histopathological data were collected.Laboratory measurements were performed at the time of CRC diagnosis and 1.5 mo and at least 6 mo after the surgical removal of the tumor.Plasma CD40L and thrombopoietin were measured via enzyme-linked immunosorbent assay,while plasma interleukin-6 was measured via electrochemiluminescence immunoassay.Patient follow-ups were terminated on January 31,2021.RESULTS Plasma CD40L of CRC patients was tendentiously higher,while platelet count(P=0.0479),interleukin-6(P=0.0002),and thrombopoietin(P=0.0024)levels were significantly higher as opposed to the control subjects.Twelve of the 106 CRC patients(11.3%)had thrombocytosis.Significantly higher CD40L was found in the presence of distant metastases(P=0.0055)and/or thrombocytosis(P=0.0294).A connection was found between CD40L and platelet count(P=0.0045),interleukin-6(P=0.0130),and thrombocytosis(P=0.0155).CD40L was constant with the course of CRC,and all baseline differences persisted throughout the whole study.Both pre-and postoperative elevated platelet count,CD40L,and interleukin-6 level were associated with poor overall and disease-specific survival of patients.The negative effect of CD40L and interleukin-6 on patient survival remained even after the stratification by thrombocytosis.CONCLUSION CD40L levels of CRC patients do not change with the course of the disease.The CD40L level is strongly correlated with platelet count,interleukin-6,thrombocytosis,and the presence of distant metastases.
出处 《World Journal of Clinical Cases》 SCIE 2022年第13期4084-4096,共13页 世界临床病例杂志
基金 Supported by the National Research,Development and Innovation Office,No.K-116128 the New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research,Development and Innovation Fund,No.UNKP-20-4-I.
  • 相关文献

参考文献2

二级参考文献57

  • 1Xiang L, Zhan Q, Zhao XH, Wang YD, An SL, Xu YZ, Li AM,Gong W, Bai Y, Zhi FC, Liu SD. Risk factors associated withmissed colorectal flat adenoma: a multicenter retrospective tandemcolonoscopy study. World J Gastroenterol 2014; 20: 10927-10937#[PMID: 25152596 DOI: 10.3748/wjg.v20.i31.10927].
  • 2Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H.Comparison of 17,641 patients with right- and left-sided coloncancer: differences in epidemiology, perioperative course, histology,and survival. Dis Colon Rectum 2010; 53: 57-64 [PMID: 20010352DOI: 10.1007/DCR.0b013e3181c703a4].
  • 3Moritani K, Hasegawa H, Okabayashi K, Ishii Y, Endo T, KitagawaY. Difference in the recurrence rate between right- and left-sidedcolon cancer: a 17-year experience at a single institution. SurgToday 2014; 44: 1685-1691 [PMID: 24126535 DOI: 10.1007/s00595-013-0748-5].
  • 4Wiggers T, Arends JW, Volovics A. Regression analysis ofprognostic factors in colorectal cancer after curative resections. DisColon Rectum 1988; 31: 33-41 [PMID: 3366023].
  • 5Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Isthere a difference in survival between right- versus left-sided coloncancers- Ann Surg Oncol 2008; 15: 2388-2394 [PMID: 18622647DOI: 10.1245/s10434-008-0015-y].
  • 6Weiss JM, Schumacher J, Allen GO, Neuman H, Lange EO,Loconte NK, Greenberg CC, Smith MA. Adjuvant chemotherapyfor stage II right-sided and left-sided colon cancer: analysis ofSEER-medicare data. Ann Surg Oncol 2014; 21: 1781-1791 [PMID:24643898 DOI: 10.1245/s10434-014-3631-8].
  • 7Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, IacopettaB. Association of tumour site and sex with survival benefitfrom adjuvant chemotherapy in colorectal cancer. Lancet2000; 355: 1745-1750 [PMID: 10832824 DOI: 10.1016/s0140-6736(00)02261-3].
  • 8Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C,Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, Roth AD,Klingbiel D, Bosman FT, Delorenzi M, Tejpar S. Distal and proximalcolon cancers differ in terms of molecular, pathological, and clinicalfeatures. Ann Oncol 2014; 25: 1995-2001 [PMID: 25057166 DOI:10.1093/annonc/mdu275].
  • 9Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, WarrenRS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, AlbertsSR. Prognostic impact of deficient DNA mismatch repair in patientswith stage III colon cancer from a randomized trial of FOLFOXbasedadjuvant chemotherapy. J Clin Oncol 2013; 31: 3664-3672[PMID: 24019539 DOI: 10.1200/jco.2013.48.9591].
  • 10Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, NelsonGD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, SinicropeFA. KRAS codon 12 and 13 mutations in relation to diseasefreesurvival in BRAF-wild-type stage III colon cancers from anadjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res2014; 20: 3033-3043 [PMID: 24687927 DOI: 10.1158/1078-0432.ccr-13-3140].

共引文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部